Cemiplimab vs Toripalimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03088540 · Phase 3 · completed

This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.

Next expected readout: December 2026 · NCT06623656 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)

Result source: NCT03088540

Toripalimab

Marketed by Coherus BioSciences, Inc. and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03856411 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06426511 (registry estimate)

Reported efficacy

MPR rate in stage III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage III population evaluated by investigators (up to 3 years); MPR rate in stage II-III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage II-III population evaluated by investigators (up to 3 years): Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. (met)

Result source: NCT04158440

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemiplimabToripalimab
PFS, median6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
8.4 vs 5.6a+2.8 vs placeboNCT03856411
OS, median21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
—Not posted · NCT03856411
ORR43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
—Not posted · NCT03856411
Duration of response, median16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
—Not posted · NCT03856411

PFS, median

Cemiplimab
6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
Toripalimab
8.4 vs 5.6a+2.8 vs placeboNCT03856411

OS, median

Cemiplimab
21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
Toripalimab
—Not posted · NCT03856411

ORR

Cemiplimab
43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
Toripalimab
—Not posted · NCT03856411

Duration of response, median

Cemiplimab
16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
Toripalimab
—Not posted · NCT03856411
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cemiplimab: 4 of 4 rows · Toripalimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabToripalimab
Dropout rate
79%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
90.7%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
90.1%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—
Discontinued due to AEs
0.3%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
0%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
0.3%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—
Serious AEs
36.8%Cemiplimaba
NCT03088540 · Phase 3
show 10 more results
27.1%Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
35.2%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
30.4%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—
Most frequent reported AEs
a
anaemia 19.7%
decreased appetite 13.8%
fatigue 13.5%
NCT03088540 · Phase 3
show 10 more results
anaemia 31.8%
alopecia 22.4%
diarrhoea 18.8%
NCT03088540 · Phase 3 · combination
anaemia 48.1% (placebo 39.9%)
neutropenia 28.7% (placebo 12.4%)
alopecia 27.8% (placebo 43.8%)
NCT03409614 · Phase 3 · combination
anaemia 33.9% (placebo 39.9%)
nausea 28.4% (placebo 16.3%)
fatigue 21.1% (placebo 8.5%)
NCT03409614 · Phase 3 · combination
anaemia 44.2% (placebo 39.9%)
alopecia 37.5% (placebo 43.8%)
nausea 25.3% (placebo 16.3%)
NCT03409614 · Phase 3 · combination
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cemiplimab

Overall Survival 23.4 vs 13.7 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
15.9 vs 13.9 Chemotherapy months
NCT03409614 · Phase 3 · combination
20.1 vs 13.9 Chemotherapy months
NCT03409614 · Phase 3 · combination
21.1 vs 12.9 placebo months
NCT03409614 · Phase 3 · combination
ORR 42.3% (n=357) vs 21.4% (n=355) Chemotherapy
responder rate · % of participants
NCT03088540 · Phase 3
show 3 more results
40.7% (n=108) vs 28.3% (n=106) Chemotherapy
NCT03409614 · Phase 3 · combination
36.7% (n=109) vs 28.3% (n=106) Chemotherapy
NCT03409614 · Phase 3 · combination
43.6% (n=312) vs 22.1% (n=154) placebo
NCT03409614 · Phase 3 · combination
Duration of Response 24.1 vs 5.9 Chemotherapy months
time to event · months
NCT03088540 · Phase 3
show 3 more results
7.8 vs 6.2 Chemotherapy months
NCT03409614 · Phase 3 · combination
15.9 vs 6.2 Chemotherapy months
NCT03409614 · Phase 3 · combination
16.4 vs 7.3 placebo months
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 4.92 vs 0.45 Chemotherapy score @ 3wk
absolute change · score
Cycle 2, Day 1 (C2D1)
NCT03088540 · Phase 3
show 2 more results
2.13 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
1.58 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 7.23 vs 1.25 Chemotherapy score @ 6wk
absolute change · score
C3D1
NCT03088540 · Phase 3
show 3 more results
4.65 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
2.75 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
0.96 vs 2.8 placebo score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.13 vs 2.43 Chemotherapy score @ 9wk
absolute change · score
C4D1
NCT03088540 · Phase 3
show 3 more results
6.22 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
3 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
1.92 vs 4.09 placebo score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.27 vs 1.88 Chemotherapy score @ 12wk
absolute change · score
C5D1
NCT03088540 · Phase 3
show 3 more results
3.31 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
4.72 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
3.35 vs 2.28 placebo score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 9.64 vs 3 Chemotherapy score @ 15wk
absolute change · score
C6D1
NCT03088540 · Phase 3
show 3 more results
5.63 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.38 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.42 vs 2.89 placebo score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.19 vs 2.55 Chemotherapy score @ 24wk
absolute change · score
C9D1
NCT03088540 · Phase 3
show 3 more results
6.87 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
1.8 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
3.65 vs 2.02 placebo score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 11.11 vs -4.17 Chemotherapy score @ 33wk
absolute change · score
C12D1
NCT03088540 · Phase 3
show 3 more results
4.44 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
9.15 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
2.37 vs 3.54 placebo score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.88 vs 5.36 Chemotherapy score @ 42wk
absolute change · score
C15D1
NCT03088540 · Phase 3
show 3 more results
7.35 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
9.4 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
6.23 vs 6.61 placebo score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.1 vs -3.03 Chemotherapy score @ 51wk
absolute change · score
C18D1
NCT03088540 · Phase 3
show 3 more results
6.73 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
14.44 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
5.28 vs 10.09 placebo score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination

+ 39 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Toripalimab's landscape